Unraveling ADC Complexities With Bio-Logic Brilliance

Tap into over two decades of innovation in Antibody-Drug Conjugates (ADCs) with a premier contract development and manufacturing organization (CDMO), powered by Pfizer and supported by a world-class manufacturing facility in Pearl River, NY. Our deep expertise in ADC development enables us to navigate the intricate challenges of bioconjugation, ensuring seamless integration from early-stage development to commercial-scale production.

At Pearl River, we specialize in the manufacturing of highly potent and cytotoxic bioconjugates, with a particular focus on ADCs and other complex molecules. Our state-of-the-art facility is designed to handle the unique requirements of these advanced therapies, offering robust process development, cutting-edge analytics, and high-containment capabilities to ensure product integrity and patient safety.

With a commitment to scientific excellence and innovation, we bring bio-logic brilliance to unravel the complexities of ADCs—empowering biopharma companies to accelerate development timelines, enhance manufacturing efficiency, and deliver life-changing therapies to patients worldwide. Partner with us to transform ADC potential into therapeutic reality.